Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?
- PMID: 20216239
- DOI: 10.1097/CMR.0b013e32833716f9
Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit?
Abstract
Surveillance schedules in patients with cutaneous melanoma (CM) aim to detect metastatic spread in an early phase of development. Few studies investigated whether detection in an early phase is associated with prolonged survival and whether the observed longer survival times are a mere consequence of detection at an earlier time point (lead time bias). This is a long-term survival analysis of 1969 patients with stage I-III CM documented during 1996-1998 in the frame of a prospective surveillance study. Development of metastatic spread was detected in 112 patients during this period and classified as early phase or advanced phase based on tumor load and operability. The impact of lead time bias on differences in survival probabilities was examined using different statistical approaches. Of 59 patients with metastases detected in an early phase of development, 64.4% died of CM, of 43 patients with advanced phase metastases 86% died (P=0.013). The 10-year overall survival probability was 42.6% for early and 25.6% for advanced phase metastases (P=0.012). This comparison remained significant after adjustment for sojourn time. Multivariate analysis identified detection of early phase metastases (P=0.022) and stage at primary diagnosis (P<0.0001) as independent prognostic factors. In conclusion, this long-term follow-up study showed a factual gain in survival time for the detection of metastasis in an early phase of development beyond lead time bias. The classification of metastasis detected in early and advanced phase may be used in future studies aiming to improve melanoma surveillance.
Similar articles
-
Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors.Cancer. 1997 Jun 15;79(12):2345-53. Cancer. 1997. PMID: 9191522
-
Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines.Ann Surg Oncol. 2007 Jun;14(6):1924-33. doi: 10.1245/s10434-007-9347-2. Epub 2007 Mar 15. Ann Surg Oncol. 2007. PMID: 17357855
-
Changing biology of cutaneous melanoma.Melanoma Res. 2008 Jun;18(3):225-9. doi: 10.1097/CMR.0b013e3282f94651. Melanoma Res. 2008. PMID: 18477898
-
Diagnosis and treatment of cutaneous melanoma: state of the art 2006.Melanoma Res. 2007 Apr;17(2):117-27. doi: 10.1097/CMR.0b013e328042bb36. Melanoma Res. 2007. PMID: 17496787 Review.
-
Surviving cutaneous melanoma: a clinical review of follow-up practices, surveillance, and management of recurrence.Surg Clin North Am. 2014 Oct;94(5):989-1002, vii-viii. doi: 10.1016/j.suc.2014.07.003. Epub 2014 Aug 5. Surg Clin North Am. 2014. PMID: 25245963 Free PMC article. Review.
Cited by
-
18 F-FDG positron emission tomography-computed tomography has a low positive predictive value for detecting occult recurrence in asymptomatic patients with high-risk Stages IIB, IIC, and IIIA melanoma.J Surg Oncol. 2022 Mar;125(3):525-534. doi: 10.1002/jso.26737. Epub 2021 Nov 6. J Surg Oncol. 2022. PMID: 34741547 Free PMC article.
-
Digital Educational Strategies to Teach Skin Self-examination to Individuals at Risk for Skin Cancer.J Health Commun. 2022 Dec 2;27(11-12):790-800. doi: 10.1080/10810730.2022.2157910. Epub 2023 Jan 10. J Health Commun. 2022. PMID: 36625227 Free PMC article. Clinical Trial.
-
Serum microRNAs as biomarkers for recurrence in melanoma.J Transl Med. 2012 Aug 2;10:155. doi: 10.1186/1479-5876-10-155. J Transl Med. 2012. PMID: 22857597 Free PMC article.
-
Stage IIA Cutaneous Melanoma: Do Regional Ultrasound and CT scan Improve Detection of Relapses? A Multicenter Retrospective Observational Study.Dermatol Pract Concept. 2024 Jul 1;14(3):e2024155. doi: 10.5826/dpc.1403a155. Dermatol Pract Concept. 2024. PMID: 39122509 Free PMC article.
-
S-100B as an extra selection tool for FDG PET/CT scanning in follow-up of AJCC stage III melanoma patients.J Surg Oncol. 2019 Nov;120(6):1031-1037. doi: 10.1002/jso.25682. Epub 2019 Aug 29. J Surg Oncol. 2019. PMID: 31468535 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical